Core Viewpoint - Micron is attempting to overturn a court ruling that allowed Yangtze Memory Technologies Corp (YMTC) access to 73 pages of confidential 3D NAND technology documents, citing national security concerns [1][4]. Group 1: Legal Dispute Overview - The legal dispute centers around YMTC's allegations of patent infringement against Micron regarding its 3D NAND storage products [2]. - A lower court had previously allowed YMTC to access the confidential documents during the evidence disclosure process, which was governed by a protective order [4][5]. - Micron has filed for a "mandamus" order with the Supreme Court to challenge the lower court's decision [1]. Group 2: Protective Order Details - The protective order limits access to sensitive materials, allowing only external lawyers and experts to handle them, while company employees are prohibited from involvement [2]. - The order also restricts the total number of paper copies to 1,500 pages, with a maximum of 30 consecutive pages [2]. - Micron claims that the number of pages requested by YMTC for the latest chip source code is ten times that of earlier chips, raising concerns about the sensitivity of the information [2][5]. Group 3: Court's Ruling and Implications - Despite Micron's objections, the court ruled that YMTC could access the 73 pages of documents, which contain information about Micron's latest and upcoming 3D NAND devices [2][4]. - The documents are strictly for reading by authorized personnel, and any form of copying or electronic reproduction is prohibited [3][5]. - Each page is tracked with a Bates number, and any unauthorized copying could lead to severe legal consequences, although there is currently no evidence of such violations by YMTC [3][5].

智通财经APP获悉，生物科技公司Halozyme Therapeutics Inc.(HALO.US)起诉默沙东(MRK.US)，试图阻 止其推出更易使用的重磅抗癌药Keytruda新剂型，指控这家制药巨头侵犯其知识产权。 根据周四向美国新泽西地区法院提交的诉讼文件，默沙东在开发可皮下注射版Keytruda(替代静脉输注 剂型)时，故意侵犯了Halozyme的专利。Halozyme要求法院禁止新版Keytruda的商业化上市——该产品 预计将于今年晚些时候推出。 Keytruda在2024年为默沙东创造近300亿美元收入，已成为癌症治疗的基石和制药史上最畅销产品。但 这款占默沙东近半数营收的药物，预计将在2028年面临低价竞争和政府定价谈判。默沙东计划在该剂型 获批后尽快让患者转换用药，这意味着任何上市延迟都可能打乱公司的长期规划。 Halozyme首席执行官海伦·托利今年3月表示，公司希望与默沙东达成授权协议，仅当计划落空时才会采 取法律行动。 皮下注射剂型对默沙东的未来增长至关重要。该公司未立即回应就诉讼置评的请求。默沙东此前曾表 示，认为Halozyme相关专利无效，并对自身法律立场充满信心。为开发注射 ...